GMAB

Business Context and Reporting Period

Company: Genmab A/S (Genmab)
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2021
Jurisdiction: Denmark (Incorporated); Reports under IFRS; Primary listing on Nasdaq Copenhagen and Nasdaq Global Select Market (ADSs).
Business Model: International biotechnology company focused on developing antibody therapeutics. Revenue is primarily derived from royalties and milestone payments from strategic partners (Janssen, Novartis, Horizon, Seagen, AbbVie) rather than direct product sales, though the company is transitioning to a commercial-stage entity with the launch of Tivdak.

Key Financial Metrics

Revenue Composition (2021):

• Total Revenue: The filing does not explicitly state the total revenue figure in the provided text, but notes that DKK 6,847 million (81% of total revenue) was derived from collaborations with Janssen.
• Janssen Contribution: DKK 6,507 million (95% of Janssen revenue) was attributable to royalties and milestones for DARZALEX.
• Revenue Mix: 82% royalties, 11% milestone revenue, 6% reimbursement revenue, and 1% collaboration revenue.

Capitalization:

• Ordinary Shares Outstanding: 65,718,456 (as of period end).
• American Depositary Shares (ADSs): 42,750,240.

Financial Position Notes:

• Accounting Basis: International Financial Reporting Standards (IFRS).
• Currency: Danish Kroner (DKK).
• Liquidity: Specific cash, cash equivalents, and debt figures are not provided in the text; the filing incorporates liquidity details by reference to the Annual Report 2021.

Material Changes vs. Prior Period

Revenue Shift:

• Janssen Dependency: Revenue from Janssen collaborations increased from 46% of total revenue in 2020 to 81% in 2021.
• AbbVie Impact: The 2020 revenue included a one-time upfront payment of $672 million (DKK 4,398 million) from AbbVie. Excluding this, Janssen accounted for 82% of revenue in 2020.
• Revenue Type: In 2021, revenue was predominantly royalties (82%) and milestones (11%). In 2020, revenue was split between royalties (47%) and license revenue (45%), reflecting the AbbVie upfront payment.

Operational Growth:

• Headcount: Employee count grew from 548 in 2019 to 1,212 at the end of 2021.
• Clinical Pipeline: Ongoing clinical trials for proprietary products increased from 12 in 2019 to 23 at the end of 2021.

Guidance, Outlook, Risks, and Unusual Items

Outlook and Strategy:

• Commercialization: Genmab is building commercialization capabilities, initially focusing on Tivdak (tisotumab vedotin) for cervical cancer in the U.S. and Japan.
• Pipeline: Seven proprietary product candidates in clinical development, including epcoritamab (Phase III initiated) and tisotumab vedotin (FDA accelerated approval received Sept 2021).
• Partnerships: Continued reliance on partners (Janssen, Novartis, Horizon) for commercialization of DARZALEX, RYBREVANT, Kesimpta, and TEPEZZA.

Key Risks:

• Concentration Risk: Financial results are substantially dependent on DARZALEX (77% of 2021 revenue). Failure by Janssen to maintain sales or adverse arbitration outcomes could materially impact revenue.
• Arbitration: Ongoing binding arbitration with Janssen regarding royalty sharing for the subcutaneous formulation and the duration of royalty obligations.
• Development Risk: High uncertainty in clinical trials; two proprietary candidates (DuoBody-CD3x5T4 and HexaBody-DR5/DR5) were discontinued in September 2021 due to insufficient data.
• Regulatory: Tivdak received accelerated approval; continued approval is contingent on confirmatory trials verifying clinical benefit.

Unusual Items:

• Discontinued Programs: Decision to stop development of DuoBody-CD3x5T4 and HexaBody-DR5/DR5 in September 2021.
• COVID-19 Impact: Potential adverse effects on clinical trials, supply chains, and sales of partnered products, though specific financial quantification is not provided in the text.

Investor Verification Checklist

• Arbitration Status: Verify the current status and potential financial impact of the arbitration with Janssen regarding DARZALEX royalties.
• Tivdak Commercialization: Assess the progress of Genmab's new commercial infrastructure and sales performance of Tivdak post-approval.
• Confirmatory Trials: Monitor the design and results of the confirmatory trial for Tivdak required to maintain FDA accelerated approval.
• Partner Performance: Review sales data for DARZALEX, RYBREVANT, Kesimpta, and TEPEZZA to gauge royalty revenue stability.
• Pipeline Progress: Track clinical data readouts for epcoritamab (Phase III) and other proprietary candidates to validate future growth prospects.
• Debt and Liquidity: Review the full Audited Financial Statements (incorporated by reference) for specific cash, debt, and working capital figures not detailed in this summary.